BACKGROUND: The response of breast cancer patients to neoadjuvant chemotherapy (NCT) is highly heterogeneous, and reliable predictive instruments remain to be defined. High-mobility group box-1 (HMGB-1) protein is a cell death marker, which is easily detectable in plasma. We hypothesized that the initial dose of NCT with epirubicin/docetaxel induces changes in plasma HMGB-1 which could allow for an early prediction of response to therapy. MATERIALS AND METHODS: First, we analysed whether epirubicin/docetaxel releases HMGB-1 from HCC1143 breast cancer cells in vitro. Thereafter, plasma HMGB-1 levels before and 1-4 days after the first dose of epirubicin/docetaxel-based NCT were determined in 41 breast cancer patients and correlated with pathological response to treatment. RESULTS: Treatment of HCC1143 cells with epirubicin/docetaxel resulted in a significant HMGB-1 release in vitro. In vivo, HMGB-1 levels increased significantly only in responders (pathological complete response or partial remission, n = 22) but not in nonresponders (stable or progressive disease, n = 19). CONCLUSION: Our data suggest that early dynamic changes of plasma HMGB1 could be a promising biomarker to predict the final response to NCT in breast cancer patients.
BACKGROUND: The response of breast cancerpatients to neoadjuvant chemotherapy (NCT) is highly heterogeneous, and reliable predictive instruments remain to be defined. High-mobility group box-1 (HMGB-1) protein is a cell death marker, which is easily detectable in plasma. We hypothesized that the initial dose of NCT with epirubicin/docetaxel induces changes in plasma HMGB-1 which could allow for an early prediction of response to therapy. MATERIALS AND METHODS: First, we analysed whether epirubicin/docetaxel releases HMGB-1 from HCC1143 breast cancer cells in vitro. Thereafter, plasma HMGB-1 levels before and 1-4 days after the first dose of epirubicin/docetaxel-based NCT were determined in 41 breast cancerpatients and correlated with pathological response to treatment. RESULTS: Treatment of HCC1143 cells with epirubicin/docetaxel resulted in a significant HMGB-1 release in vitro. In vivo, HMGB-1 levels increased significantly only in responders (pathological complete response or partial remission, n = 22) but not in nonresponders (stable or progressive disease, n = 19). CONCLUSION: Our data suggest that early dynamic changes of plasma HMGB1 could be a promising biomarker to predict the final response to NCT in breast cancerpatients.
Authors: Jill M Miller; Joyce K Thompson; Maximilian B MacPherson; Stacie L Beuschel; Catherine M Westbom; Mutlay Sayan; Arti Shukla Journal: Cancer Prev Res (Phila) Date: 2014-01-15
Authors: Oliver Kepp; Laura Senovilla; Ilio Vitale; Erika Vacchelli; Sandy Adjemian; Patrizia Agostinis; Lionel Apetoh; Fernando Aranda; Vincenzo Barnaba; Norma Bloy; Laura Bracci; Karine Breckpot; David Brough; Aitziber Buqué; Maria G Castro; Mara Cirone; Maria I Colombo; Isabelle Cremer; Sandra Demaria; Luciana Dini; Aristides G Eliopoulos; Alberto Faggioni; Silvia C Formenti; Jitka Fučíková; Lucia Gabriele; Udo S Gaipl; Jérôme Galon; Abhishek Garg; François Ghiringhelli; Nathalia A Giese; Zong Sheng Guo; Akseli Hemminki; Martin Herrmann; James W Hodge; Stefan Holdenrieder; Jamie Honeychurch; Hong-Min Hu; Xing Huang; Tim M Illidge; Koji Kono; Mladen Korbelik; Dmitri V Krysko; Sherene Loi; Pedro R Lowenstein; Enrico Lugli; Yuting Ma; Frank Madeo; Angelo A Manfredi; Isabelle Martins; Domenico Mavilio; Laurie Menger; Nicolò Merendino; Michael Michaud; Gregoire Mignot; Karen L Mossman; Gabriele Multhoff; Rudolf Oehler; Fabio Palombo; Theocharis Panaretakis; Jonathan Pol; Enrico Proietti; Jean-Ehrland Ricci; Chiara Riganti; Patrizia Rovere-Querini; Anna Rubartelli; Antonella Sistigu; Mark J Smyth; Juergen Sonnemann; Radek Spisek; John Stagg; Abdul Qader Sukkurwala; Eric Tartour; Andrew Thorburn; Stephen H Thorne; Peter Vandenabeele; Francesca Velotti; Samuel T Workenhe; Haining Yang; Wei-Xing Zong; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi Journal: Oncoimmunology Date: 2014-12-13 Impact factor: 8.110